Medical Science and Technology Achievements: To "flower" and "results"

“Investors like products that will be available soon. But we only made a prototype, and we have to get a product registration certificate at least 10 to 20 million.” Not long ago, the capital medical department Wang Ningli, director of the Eye Center of Beijing Tongren Hospital affiliated to the University and director of the Beijing Eye Research Institute, encountered such a headache in the process of leading the team to develop the prototype of the tonometer. The research and development is to benefit the health of the people, but the question of who should cultivate the product incubation period has become an obstacle in the process of transformation of results.

Under the background of healthy China construction and technological innovation, medical innovation has been mentioned as an unprecedented important position, and the reform of relevant institutional mechanisms is also steadily advancing. However, from the actual situation, clinicians still have many thresholds in the process of transforming medical innovation results. In the interview, the reporter found that the resistance to the transformation of the “tonometer” was not a single case, and how the medical innovation achievements really landed became an urgent problem to be solved.

Who will cultivate during the product incubation period?

Who should cultivate the product incubation period, which has become a “blocking tiger” in the transformation of medical innovation and scientific and technological achievements. What is hurt by it is not only Wang Ningli, but also thousands of medical workers who are concerned about innovation and look forward to the early application of innovative results to the clinic.

Wu Yuming, a pediatric surgeon at Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, has a similar experience with Wang Ningli. Ten years ago, after a series of improvements, he developed the "Break Protection Bag" which was supported by many government research projects such as the Shanghai Science and Technology Commission, and also obtained invention patents, but the "last mile" of industrial transformation. But it touched the wall. Wu Yuming said that because the incidence of abdominal fissure is not high, the number of clinically used bags is small each year. “Some manufacturers were very happy to hear this information at first, but after the investigation, they found that this is a Class II medical device. The input and output of R&D is disproportionate. Especially when clinical trials cost a lot of money, they close the door of transformation.”

It is true that in the current chain of innovation achievements, from the initial research and development results to the release of applicable products, there is a lack of stable financial support. In more cases, scientists need to find their own venture capital funds, and there are no more channels. To this end, Wang Ningli once suggested that “if at this stage, the national incubator fund can be combined with private venture capital funds, the risk is shared by the state and investment institutions, which can enhance the enthusiasm of investors and thus promote product conversion. speed".

Make a good combination of "healing and labor"

As we all know, engineering R & D personnel do not understand the clinical needs due to lack of medical background; while doctors know the clinical pain points, they do not know how to solve problems through engineering technology. In this regard, Wang Ningli proposed to strengthen the combination of medical and industrial, and jointly promote medical innovation. And this can precisely solve the problem of insufficient strength in the creative design of doctors' medicines in China due to the difference between the domestic medical student education system and the West.

After the combination of the two, the doctors put forward the clinical needs, the engineers are responsible for product design, the two sides constantly modify the design in communication and collaboration, and finally return to the clinical trial and evaluation. In this interactive process, the two sides can play their strengths and complement each other to achieve the development and innovation of medical products .

A seminar on immersive computing and artificial intelligence technology in autism interventions recently held in Shanghai is a model for effective integration of medical workers. Experts from the Mental Health Center affiliated to Shanghai Jiao Tong University School of Medicine teamed up with scientists from the School of Electronic Information and Electrical Engineering to bring new hope to the group of children known as "stars."

Professor Zhai Guangtao from the School of Electronic Information and Electrical Engineering of Shanghai Jiaotong University introduced this combination of medical and labor research. The core characteristics of virtual reality technology are immersion, interactivity and imagination. The basic symptoms of patients with autism spectrum disorders can be summarized as Lack of social, interactive and imaginative aspects. The characteristics of virtual reality technology correspond to it, so it is very suitable for the adjuvant treatment of children's autism spectrum disorder.

Policies are good for stimulating medical innovation

In September last year, Shanghai began to implement the “Second Class Medical Device Priority Approval Procedures”. Those medical devices that are urgently needed in clinical practice and listed in the national or city science and technology major projects or key research and development programs will be sorted separately in the approval process, giving priority to review. To ensure that it can be listed at the fastest speed in a safe situation, to solve problems for patients. This is also a “green channel” opened up by Shanghai for medical technology innovation.

In recent years, relevant policies have been introduced at both the national level and the local level to encourage innovation in pharmaceuticals and medical devices. Yu Weifeng, former director of the Department of Anesthesiology at Renji Hospital of Shanghai Jiaotong University School of Medicine and former president of the Anesthesiologists Branch of the Chinese Medical Doctor Association, deeply felt that “long-term problems plaguing medical researchers, such as the adoption and review of overseas clinical trial data. We have been motivated by the simplification of the approval process and so on."

For example, he said, "There are patients who have induced a rare 'malignant hyperthermia' disease because of the injection of anesthetic during the operation. The only medicine that can save lives is dantrolene." However, dantrolene is more special, and the shelf life is only half a year. More than 30 such patients, “whether importing or domestically producing generic drugs, they are facing problems such as insufficient clinical trial samples and difficulties in profitability.” As the policy is further improved, he believes that more medical innovations will be strictly controlled as soon as possible. Enter the results transformation channel for the benefit of patients.

The number says:

37 items: In 2017, Beijing municipal hospitals reported 85 key scientific and technological achievements with transformation value, 129 patents granted, and 37 technology transfer contracts, involving medical devices, diagnostic reagents, traditional Chinese medicines, chemical drugs, biological drugs and software. Systems and other fields.

39%: In 2017, China has established 32 national clinical medical research centers in 11 disease areas including cardiovascular diseases and neurological diseases. The Clinical Medical Research Center has established close cooperative relations with relevant research units, universities, and innovative enterprises. On average, it has obtained 91 scientific and technological achievements patents for major new drugs and medical devices every year, which is 39% higher than that before the establishment of the research center.

17th: At present, the number of invention patents and authorizations in China ranks first in the world, the total number of international scientific papers ranks second in the world, and the number of effective invention patents ranks third in the world. However, compared with the number of scientific and technological achievements and the number of patents, our national innovation capability ranks 17th, and the conversion rate of scientific and technological achievements and the contribution to the economy and society still have room for improvement. (Science Network)

Dmt Dimethyl Tryptamine

Product Information:

Manufacturer supply sell high quality tryptamine CAS 61-54-1

Tryptamine CAS:61-54-1 is a monoamine alkaloid. It contains an indole ring structure, and isstructurally similar to the amino acid tryptophan, from which the name derives. Tryptamine

CAS:61-54-1 is found in trace amounts in the brains of mammals and is hypothesized to play a role as a neuromodulator or neurotransmitter.It is used in biological and pharmaceutical intermediates,with vasoactive, possibly neuromodulatory and other functions.

Name	Factory supply Dimethyl Tryptamine powder cas 61-54-1 with low price Tryptamine
Other name	1H-Indole-3-ethanamine;2-(1H-Indol-3-yl)ethanamine;3-(3-indolyl)ethylamine;4-2-Indol-3-yl-aethylamin;2-indol-3-ylethylamine;2-indol-3-yl-ethylamine;3-(2-aminoethyl)indole;
CAS	61-54-1
Molecular formula	C10H12N2
Molecular weight	160.22
Appearance	White or light yellow crystal
Purity	98%
Application	Organic intermediate;
Package	100g, 500g, 1Kg Aluminum plastic composite bag or 25kg cardboard barrel

Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.

Product Photo:

Dmt Dimethyl Tryptamine,Nutrition Supplement Powder,Bulk Bcaa Powder,Bcaa 2:1:

Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropic.com